AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ChAdV63.HIVconsv booster vaccine
Description: ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv booster vaccine
Description: ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA.HIVconsv booster vaccine
Description: MVA.HIVconsv 2 x 10\^8 pfu at week 20
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv booster vaccine
Description: MVA.HIVconsv 2 x 10\^8 pfu at week 20
Study NCT02425241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPHPC
Description: 40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
Study NCT02425241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
Study NCT00142688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
Study NCT00142688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
Study NCT00516828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: subcutaneously twice daily from Day 1 to 10
Study NCT00871819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Precision Spinal Cord Stimulation (SCS)
Description: Various SCS device programming parameters
Study NCT00631384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples VCT
Description: Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
Study NCT00631384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual VCT
Description: Women to receive individual VCT
Study NCT00905359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aperius™ PercLID™ System
Description: Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
Study NCT00905359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standalone Decompressive Surgery
Description: Lumbar decompressive surgery without instrumentation or fusion
Study NCT00616330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate/butoconazole nitrate
Description: semi solid, single dose
Study NCT00616330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate
Description: semi solid, single dose
Study NCT00616330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: butoconazole nitrate
Description: semi solid, single dose
Study NCT01003171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS-2 soft-gel capsule
Description: MCS-2 30 mg/day
Study NCT04648098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge training and telephone counseling
Description: The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call.
Study NCT04011423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable shoes plus Whole-body vibration
Description: Wearing unstable shoes during the whole-body vibration training
Study NCT04011423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable shoes plus Whole-body vibration
Description: Wearing stable shoes during the whole-body vibration training
Study NCT02442245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: XSurge
Description: During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
Study NCT02442245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Microcrystalline Cellulose
Study NCT02802319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine Xenograft (Zcore)
Description: Ridge preservation bone grafting after tooth extraction
Study NCT02802319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Xenograft (Bio-Oss)
Description: Ridge preservation bone grafting after tooth extraction
Study NCT01184001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Study NCT01184001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
Study NCT04358419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aspergillus specific proteins in exhaled breath condensate (EBC)
Description: The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
Study NCT04358419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)
Description: The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
Study NCT02831309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light-Intensity Condition
Description: The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
Study NCT02831309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Condition
Description: The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
Study NCT02831309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Condition
Description: The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
Study NCT02831309 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sedentary Condition
Description: The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
Study NCT01807221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Study NCT02442245 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control: No supplementation
Study NCT02812875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-170
Description: Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer.
Study NCT02051569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Tryptophan and placebo are given in a crossover design, based on randomisation.
Study NCT00820664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace 0.5 mg
Description: 0.5 mg tablet taken once daily for 28 days
Study NCT00820664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace 2 mg
Description: 2 mg tablets taken once daily for 28 days.
Study NCT00820664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo 0 mg capsule taken once daily for 28 days
Study NCT02739776 — intervention group
Intervention type: DEVICE
Intervention: Thermographic imaging
Description: Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
Study NCT00468130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Study NCT00468130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Study NCT00006010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00006010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01031849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Description: Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
Study NCT02542423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endocan blood test samples
Study NCT00742027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat hard gelatin capsules.
Study NCT01911780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching amlodipine capsule
Study NCT01911780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan + HCTZ
Description: FDC tablet
Study NCT01911780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan + HCTZ
Description: FDC tablet
Study NCT01911780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: capsule
Study NCT03580499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Given PO
Study NCT03580499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03988972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diathermy
Description: In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
Study NCT03988972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel
Description: Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
Study NCT03922204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-145
Description: full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
Study NCT03922204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
Study NCT06730789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicondylitis bandage
Description: A conservative treatment method of lateral epicondylitis.
Study NCT06730789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist dorsiflexion splint
Description: A conservative treatment method of lateral epicondylitis.
Study NCT06730789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: A conservative treatment method of lateral epicondylitis
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT03761225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04026711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinol
Description: Mitoquinol (MitoQ) 40 mg per day for 12 weeks
Study NCT04026711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo daily for 12 weeks
Study NCT01739764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
Study NCT02862132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Study NCT02781376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA OSA
Description: Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
Study NCT02781376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Snoring Identification Only
Description: Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
Study NCT00437372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy.
Study NCT00437372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
Study NCT03886389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP
Description: Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
Study NCT01980745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate 250mg
Description: Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
Study NCT01980745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03752060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
Study NCT03752060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
Study NCT01807221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01807221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02634944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)
Study NCT02634944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vestibular Ocular Motor Screening Tool (VOMS)
Description: Vestibular Ocular Motor Screening Tool (VOMS)
Study NCT04457934 — intervention group
Intervention type: DRUG
Intervention: Plenvu
Description: All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
Study NCT03107533 — intervention group
Intervention type: OTHER
Intervention: Video recording of clinical visit
Description: For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
Study NCT00842777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent manualized group treatment
Description: Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment
Study NCT00842777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent self-help groups
Description: Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
Study NCT02981563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Together
Description: For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
Study NCT02420483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation chest compressions
Study NCT00123682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proactive outreach to counseling
Description: Project staff reach out to engage referred smoker into telephone counseling
Study NCT00123682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reactive outreach to counseling
Description: Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
Study NCT00123682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Description: Multi-session telephone counseling, delivered by California Smokers' Helpline
Study NCT01807221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspra (eplerenone)
Study NCT03545113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper arm arteriovenous graft surgery
Description: Creation of arteriovenous graft vascular access for hemodialysis
Study NCT03545113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arm arteriovenous fistula surgery
Description: Creation of arteriovenous fistula vascular access for hemodialysis